New study explores psychedelic therapy for co-occurring cocaine addiction and depression
A team of UTHealth Houston researchers has been awarded a five-year, $3.4 million grant to study whether psilocybin-assisted therapy is a viable treatment option for individuals with co-occurring cocaine use disorder and major depressive disorder.
Read original article on The Medical News →Related news
-
Needle-free mRNA vaccines protect mice against COVID-19 and flu
United Kingdom
-
LSD speeds up brain waves and increases neural complexity, study finds
United Kingdom
-
INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar
United Kingdom
-
New national trial platform aims to accelerate Alzheimer's disease prevention
United Kingdom
-
Stem cell therapies may need new protein quality control standards
United Kingdom
-
Review offers guidance for managing recurrent catheter-related bloodstream infections
United Kingdom
-
Digital mindfulness program cuts depression relapse risk in mothers by 26%
United Kingdom
-
Cardiac events account for 43% of on-duty firefighter deaths
United Kingdom